Evidence map›Paper›PMID 34710432›Full record

ArticleJournal of lipid research2022

Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.

Oleg Kovrov, Fredrik Landfors, Valeria Saar-Kovrov, Ulf Näslund, Gunilla Olivecrona

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of lipid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01849575 (Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01849575 naactive not recruitingnot on this map

Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme (VIP) and Ordinary Care.

TypeinterventionalSponsorUmeå UniversityRan2013 to 2027Enrolled3,532ConditionsCardiovascular DiseasesArmsIntervention
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Oleg KovrovDepartment of Medical Biosciences, Umeå University, Umeå, Sweden.
Fredrik LandforsDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Valeria Saar-KovrovDepartment of Medical Biosciences, Umeå University, Umeå, Sweden; Department of Pathology, CARIM School for Cardiovascular Diseases MUMC+, Maastricht University, Maastricht, The Netherlands.
Ulf NäslundHeart Centre and Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Gunilla OlivecronaDepartment of Medical Biosciences, Umeå University, Umeå, Sweden. Electronic address: Gunilla.Olivecrona@umu.se.
Umeå University · SEMaastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LPL is a key player in plasma triglyceride metabolism. Consequently, LPL is regulated by several proteins during synthesis, folding, secretion, and transport to its site of action at the luminal side of capillaries, as well as during the catalytic reaction. Some proteins are well known, whereas others have been identified but are still not fully understood. We set out to study the effects of the natural variations in the plasma levels of all known LPL regulators on the activity of purified LPL added to samples of fasted plasma taken from 117 individuals. The enzymatic activity was measured at 25°C using isothermal titration calorimetry. This method allows quantification of the ability of an added fixed amount of exogenous LPL to hydrolyze triglyceride-rich lipoproteins in plasma samples by measuring the heat produced. Our results indicate that, under the conditions used, the normal variation in the endogenous levels of apolipoprotein C1, C2, and C3 or the levels of angiopoietin-like proteins 3, 4, and 8 in the fasted plasma samples had no significant effect on the recorded activity of the added LPL. Instead, the key determinant for the LPL activity was a lipid signature strongly correlated to the average size of the VLDL particles. The signature involved not only several lipoprotein and plasma lipid parameters but also apolipoprotein A5 levels. While the measurements cannot fully represent the action of LPL when attached to the capillary wall, our study provides knowledge on the interindividual variation of LPL lipolysis rates in human plasma.

Indexed as

Lipoprotein LipaseAdultAngiopoietin-Like Protein 3Angiopoietin-Like Protein 8Angiopoietin-like ProteinsFastingFemaleHumansHydrolysisLipoproteinsLipoproteins, VLDLMaleMiddle AgedPeptide HormonesTriglyceridesAngiopoietin-Like Protein 3Angiopoietin-Like Protein 8Angiopoietin-like ProteinsANGPTL3 protein, humanANGPTL8 protein, humanLipoprotein LipaseLipoproteinsLipoproteins, VLDLPeptide HormonesTriglyceridesangiopoietin-like proteinsapolipoproteinscapillariesexogenous LPLisothermal titration calorimetrylipidomicslipid signatureplasma triglyceride metabolismVLDL particle size

Identifiers

PMID34710432
PMCPMC8953621
OpenAlexW3210546376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.